Breaks Categories: News

MondayNov 20, 2023 3:08 pm

NetworkNewsBreaks – Flux Cofounder Spotlighted in Latest CryptoNewsAudio Production Released by IBN

Flux, a decentralized Web3 cloud infrastructure comprised of user-operated, scalable and globally distributed computational nodes, was featured in the most recent episode of the CryptoNewsAudio Podcast, released by IBN, a multifaceted communications organization, as part of its strategic efforts to provide specialized content distribution via widespread syndication channels. The episode features Flux cofounder Daniel Keller, who believes Flux is the best-kept secret in the blockchain space. He pointed out that, up to this point, blockchain has been “mostly speculatory,” with a majority of the development dollars being devoted to marketing and PR while also “creating this FOMO, or frothiness, that comes…

Continue Reading

MondayNov 20, 2023 3:01 pm

NetworkNewsBreaks — SenesTech Inc. (NASDAQ: SNES) Announces Expanded Distribution with DIY Pest Control Partner, Exclusive Fertility Control Product

SenesTech (NASDAQ: SNES), the leader in fertility control to manage animal pest populations, has renewed and expanded its distribution with DIY Pest Control. The expansion includes a stocking order for Evolve(TM) Soft Bait, the first and only soft bait product featuring breakthrough, next-generation technology that targets rodent populations by using nonlethal methods to restrict fertility. A leading online distributor of pest control, DIY Pest Control is a family-owned business that services and supplies pest-control companies and consumers. According to the announcement, SNES’s Evolve targets a rat’s ability to rapidly reproduce, effectively reducing fertility in rodents in numerous independent studies. “We…

Continue Reading

MondayNov 20, 2023 2:36 pm

NetworkNewsBreaks – Safety Shot Inc. (NASDAQ: SHOT) Set for Dec. 7 California Launch

Safety Shot (NASDAQ: SHOT) today announced the west coast launch of Safety Shot, the first patented beverage on Earth that helps people feel better faster by reducing blood alcohol content and boosting clarity. Safety Shot is a nutraceutical functional beverage, created by industry experts and validated by research, that accelerates the body’s break-down of alcohol while aiding in recovery and rehydration. “Our west coast launch in the Los Angeles area is aligned with our national online direct-to-consumer sales launch through our own website and through Amazon. We are super excited to have people try Safety Shot. We have given out…

Continue Reading

MondayNov 20, 2023 2:18 pm

NetworkNewsBreaks – PaxMedica Inc. (NASDAQ: PXMD) Announces Pricing of $7M Public Offering

PaxMedica (NASDAQ: PXMD), a biopharmaceutical company focused on advancing treatments for neurological disorders, today announced the pricing of its public offering of an aggregate of 5,384,615 shares of its common stock (or common stock equivalents in lieu thereof) and warrants to purchase up to 5,384,615 shares of common stock, at a combined public offering price of $1.30 per share (or common stock equivalent in lieu thereof) and accompanying warrant. According to the announcement, the warrants will be exercisable immediately upon issuance, at an exercise price of $1.30 per share, and will expire five years after the initial exercise date. Subject…

Continue Reading

FridayNov 17, 2023 1:14 pm

NetworkNewsBreaks – FingerMotion Inc. (NASDAQ: FNGR) Releases Update on Federal Lawsuit Filed Against Research Firm

FingerMotion (NASDAQ: FNGR), a mobile services and data company, is reporting an update on the federal lawsuit it filed against Capybara Research last month; the lawsuit alleges that Capybara maliciously published a defamatory article in a premediated attempt to move the public market for FingerMotion's stock lower to benefit from its previously announced short position. According to the update, the company and its litigation counsel, with cooperation from third parties, has spent weeks of work investigating the allegations. As a result, the person responsible for the malicious article has been identified, and the company is taking steps to add that…

Continue Reading

FridayNov 17, 2023 12:34 pm

NetworkNewsBreaks — DegenX Unveils Groundbreaking Upgrade in Multichain Token Swaps

DegenX, a native Avalanche DeFi project, has launched Broccoliswap, a user-focused, cross-chain aggregator. According to the announcement, this innovative upgrade in multichain token swaps enables seamless swapping of any token between networks. The new platform offers an array of other benefits for crypto users, including the ability to auto-prompt and switch to the correct network for a transaction, a “fix” button that finds assets if a third-party bridge transaction fails and recent trade history. Broccoliswap also auto applies appropriate slippage for a chosen token and creates Direct Trade links for favorite pairings. Designed with ease of use in mind, Broccoliswap…

Continue Reading

FridayNov 17, 2023 10:40 am

NetworkNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) Releases Date for Planned Distribution of Celly Nu Shares

FSD Pharma (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions, has announced the distribution date that its securityholders can expect to receive common shares in the capital of Celly Nutrition Corp. The distribution is subject to the satisfaction of all applicable closing conditions of the arrangement. The arrangement outlines plans for FSD Pharma securityholders to receive one Celly Nu share for each FSD Pharma share or FSD Pharma distribution warrant that they hold. FSD Pharma anticipates that this will result in approximately 45,694,621 Celly Nu shares being distributed…

Continue Reading

FridayNov 17, 2023 10:20 am

NetworkNewsBreaks — PaxMedica Inc. (NASDAQ: PXMD) News of FDA Type-B Meeting Shared in Syndicated Audio Broadcast

PaxMedica (NASDAQ: PXMD), a biopharmaceutical company focused on advancing treatments for neurological disorders, is spotlighted in a recent NetworkNewsAudio broadcast. According to the broadcast, the company recently announced that it had met with the U.S. Food and Drug Administration (“FDA”) in a Type-B meeting, designed to discuss the positive results from the company’s PAX-HAT-301 study of suramin in stage one human African sleeping sickness caused by Trypanosoma brucei rhodesiense, a rare and fatal parasitic disease. The broadcast was released by via NetworkNewsAudio (“NNA”), a solution that offer companies additional visibility, recognition and brand awareness in the investment community via distribution…

Continue Reading

ThursdayNov 16, 2023 3:12 pm

NetworkNewsBreaks – HyperSense Software Earns Clutch Titles, Reflecting Dedication to Tech Innovation

HyperSense Software, a leading figure in software development and digital transformation, today announced its dual recognition as a Clutch Global and Clutch Champion winner, marking its entry into the top 10% of digital providers worldwide. According to the announcement, Clutch’s list of 2023 Champions, released on Nov. 14, spotlights HyperSense Software for its outstanding industry expertise and commitment to client satisfaction. The distinction underscores the company’s growth trajectory, following its recent expansion into the U.S. with a new Chicago office. “Earning both Clutch Global and Clutch Champion titles is a landmark achievement for HyperSense Software,” the company’s CTO Andrei Neacsu…

Continue Reading

ThursdayNov 16, 2023 3:07 pm

NetworkNewsBreaks – Vertex Pharmaceuticals Inc. (NASDAQ: VRTX) Featured in Barron’s Article for Potential Near ‘Breakthrough’

Vertex (NASDAQ: VRTX), a global biotechnology company that invests in scientific innovation to create transformative medicines, was featured in a recent Barron’s article. The piece, titled “This New Pain Pill Could Replace Opioids. It’s an Opportunity for Investors,” delves into the opioid epidemic and a potential alternative — a new Vertex drug candidate that is currently undergoing clinical trials. “A nonaddictive pain pill that works as well as an opioid, with none of the same addiction risk and side effects, would be an instant blockbuster,” the article reads. It further describes rising demand in the U.S., where Americans filled roughly…

Continue Reading